1. Home
  2. GRMN vs INSM Comparison

GRMN vs INSM Comparison

Compare GRMN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Garmin Ltd. (Switzerland)

GRMN

Garmin Ltd. (Switzerland)

HOLD

Current Price

$195.41

Market Cap

40.5B

Sector

Industrials

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$207.66

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRMN
INSM
Founded
1990
1988
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.5B
41.2B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
GRMN
INSM
Price
$195.41
$207.66
Analyst Decision
Hold
Strong Buy
Analyst Count
4
19
Target Price
$239.50
$173.35
AVG Volume (30 Days)
1.1M
2.8M
Earning Date
10-29-2025
10-30-2025
Dividend Yield
1.84%
N/A
EPS Growth
3.11
N/A
EPS
8.11
N/A
Revenue
$6,943,125,000.00
$447,022,000.00
Revenue This Year
$15.45
$40.09
Revenue Next Year
$6.78
$129.64
P/E Ratio
$24.09
N/A
Revenue Growth
16.56
30.34
52 Week Low
$169.26
$60.40
52 Week High
$261.69
$209.77

Technical Indicators

Market Signals
Indicator
GRMN
INSM
Relative Strength Index (RSI) 32.28 70.03
Support Level $186.67 $202.27
Resistance Level $194.27 $209.77
Average True Range (ATR) 3.97 6.68
MACD 1.51 -0.06
Stochastic Oscillator 50.07 89.91

Price Performance

Historical Comparison
GRMN
INSM

About GRMN Garmin Ltd. (Switzerland)

Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: